Drawing for Serial No. 87497304

USPTO serial 87497304

Serial No. 87497304

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
HESIK, APRIL ANNE
Law office
DIVISIONAL UNIT

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with Serial No. 87497304?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Stephanie K. Wade

Stephanie K. Wade Sughrue Mion, PLLC2000 Pennsylvania Ave., Suite 900Washington, DC 20006UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Biochemicals for scientific, laboratory, and research use, namely, proteolytically-activatable, protease-activatable, or proteolytically activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells and antigens; diagnostic kits for scientific, laboratory, and research use comprising proteolytically-activatable or protease-activatable, proteolytically-activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells, and antigens; immunoglobulin and antigen-binding fragments for drug conjugation and targeted cell binding for laboratory and research use; assays and reagents for use in scientific, laboratory and research purposes; biochemical test kits comprising assays and reagents for scientific, laboratory and research purposes; assay kits comprising assays and reagents for measuring, monitoring, testing and analyzing proteolytic activation and antibody binding for scientific, laboratory and research useACTIVE—
005Infections, inflammation; infections, inflammation; infections, inflammation; engineered cell therapies for medical purposes, namely, for use in treating cancer, infections, autoimmunity, and inflammation; infections, inflammation; assays and reagents for use in medical, medical diagnostic and therapeutic purposes for proteolytic activation and binding to tumor cells; biochemical test kits comprised of assays and reagents for medical, medical diagnostic and therapeutic purposes for proteolytic activation and binding to tumor cells; assay kits comprised of assays and reagents for measuring, monitoring, testing and analyzing proteolytic activation, antibody binding, therapeutic treatments and patient recovery for medical, medical diagnostic and therapeutic purposes; assay kits comprised of assays and reagents for use in identifying candidate patient populations for specific therapeutic treatments for medical purposes; therapeutic kits comprising proteolytically-activatable or protease-activatable, proteolytically-activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells, and antigensACTIVE—
042Scientific research and development in the field of therapeutic biochemicals, engineered cell therapies and immunotherapy, oncology and dysregulated proteolytic activity; medical and scientific research and development for agents, preparations, products and technology in the field of dysregulated proteolytic activities; providing medical and scientific research information in the fields of biochemicals, engineered cell therapies, immunotherapy, oncology and dysregulated proteolytic activity; scientific investigations for medical purposes; medical research; providing scientific and medical research information and analysis relating to biochemicals, engineered cell therapies and immunotherapy, proteolytic activation, antibody binding, therapeutic treatments, patient recovery, and the identification of candidate patients for specific therapeutic treatments; testing, research, design and development services in the field of biochemicals for scientific and medical research purposes; research, design and development of assays for measuring, monitoring, testing and analyzing proteolytic activation, antibody binding, therapeutic treatments and patient recovery, and for identifying candidate patient populations for specific therapeutic treatments; providing technical support and consultation services relating to antibody selection and use, namely, providing technical scientific research consultation services; online computer services in the nature of providing a search engine for obtaining data, namely, searching, retrieving, and providing information on antibodies and research topics pertaining to antibodies on a global computer networkACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Apr 5, 2021MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Apr 5, 2021ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Aug 1, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 31, 2020EX5GSOU EXTENSION 5 GRANTED—
Jul 29, 2020EXT5SOU EXTENSION 5 FILED—
Jul 29, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 7, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 5, 2020EX4GSOU EXTENSION 4 GRANTED—
Feb 5, 2020EXT4SOU EXTENSION 4 FILED—
Feb 5, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 30, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 30, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jan 21, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 21, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 16, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 16, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 22, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 19, 2019EX3GSOU EXTENSION 3 GRANTED—
Aug 19, 2019EXT3SOU EXTENSION 3 FILED—
Aug 19, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 19, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 15, 2019EX2GSOU EXTENSION 2 GRANTED—
Feb 15, 2019EXT2SOU EXTENSION 2 FILED—
Feb 15, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 18, 2018NOACCORRECTED NOA E-MAILED—
Sep 18, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 17, 2018EX1GSOU EXTENSION 1 GRANTED—
Sep 17, 2018DPCCDIVISIONAL PROCESSING COMPLETE—
Sep 17, 2018AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Aug 21, 2018DRRRDIVISIONAL REQUEST RECEIVED—
Aug 21, 2018ERTDTEAS REQUEST TO DIVIDE RECEIVED—
Aug 20, 2018EXT1SOU EXTENSION 1 FILED—
Aug 20, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 27, 2018NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Feb 20, 2018CHPBPOST PUBLICATION AMENDMENT - ENTERED—
Feb 16, 2018APETASSIGNED TO PETITION STAFF—
Feb 6, 2018EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
Jan 2, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 2, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 13, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 26, 2017ALIEASSIGNED TO LIE—
Nov 14, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 14, 2017XAECEXAMINER'S AMENDMENT ENTERED—
Nov 14, 2017GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Nov 14, 2017GNEAEXAMINERS AMENDMENT E-MAILED—
Nov 14, 2017CNEAEXAMINERS AMENDMENT -WRITTEN—
Nov 10, 2017ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Nov 10, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 9, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 8, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 8, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 24, 2017GEANNOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Jul 24, 2017GEAPEXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Jul 24, 2017EPENCOMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY—
Jul 24, 2017CPEAEXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED—
Jul 17, 2017DOCKASSIGNED TO EXAMINER—
Jun 28, 2017MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Jun 27, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 23, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance